TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17096458

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial treatment assignment
Number of subjects: 0
Study: 15358015

Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) with P-32 (20 Gy at 1 mm in the coronary wall) after direct stenting
Number of subjects: 112

Group type: COMPARATOR
Intervention: No VBT (control group)
Number of subjects: 112
Study: 11756905

Group type: EXPERIMENTAL
Intervention: Outpatient care (early discharge)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 95
Study: 9659862

Group type: EXPERIMENTAL
Intervention: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavior therapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (16 sessions of weekly cognitive behavior therapy)
Number of subjects: 62
Study: 8925521

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMC)
Number of subjects: 0
Study: 2540724

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of lithium carbonate and imipramine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study: 19510

Group type: EXPERIMENTAL
Intervention: Butaclamol (up to 50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Butaclamol (maintenance dose of 5 to 20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ)
Number of subjects: 0
Study: 31641058

Group type: EXPERIMENTAL
Intervention: CR messages with addiction warning
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: CR messages without addiction warning
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: NFS followed by CR messages with addiction warning
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: NFS condition
Number of subjects: 1528
Study: 31429792

Group type: EXPERIMENTAL
Intervention: Covered stents (Advanta V12 over-the-wire, Atrium Maquet Getinge Group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bare-metal stents (Palmaz Blue with rapid-exchange delivery system, Cordis Corporation)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 84
Study: 29157591

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 24824772

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Cycling (MICC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Cycling (HIIC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short-Duration High-Intensity Intermittent Cycling (S-HIIC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting Control
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All exercise bouts (MICC, HIIC, S-HIIC)
Number of subjects: 12
Study: 25001274

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg and 80 mg
Number of subjects: 133
Study: 21734423

Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting SAP microspheres
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional TACE (control group)
Number of subjects: 30
Study: 18443391

Group type: EXPERIMENTAL
Intervention: Multifaceted psychiatric intervention conducted by a psychiatric liaison nurse and/or referral to a liaison psychiatrist, followed by advice to the treating physician or organization of a multidisciplinary case conference.
Number of subjects: 247

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Multifaceted psychiatric intervention
Number of subjects: 247
Study: 16809729

Group type: EXPERIMENTAL
Intervention: Alfimeprase 3.0 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alfimeprase 1.0 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alfimeprase 0.3 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Alteplase 2.0 mg
Number of subjects: 55
Study: 14663215

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10800630

Group type: COMPARATOR
Intervention: Tetrazepam-ratiopharm film-coated tablets (test preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tablets of a reference preparation (reference preparation)
Number of subjects: 20
Study: 8653995

Group type: EXPERIMENTAL
Intervention: Thioridazine 100 mg for 14 days
Number of subjects: 21
Study: 1458567

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) at 330 mg/m2 per week for colorectal cancer (167 mg/m2 daily for the first 3 months), Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks for gastric cancer. 5-FU at 1,000 mg/m2 every week for 19 colorectal cancer patients.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Implantable port system for repeated hepatic arterial infusion chemotherapy.
Number of subjects: 84
Study: 6718925

Group type: EXPERIMENTAL
Intervention: Predominantly horizontal EOG activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predominantly vertical EOG activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dream narratives and corresponding EOG recordings
Number of subjects: 0
Study: 30963404

Group type: EXPERIMENTAL
Intervention: Dietary dragon fruit peel powder (DFPP) at levels of 0, 1, 2, 3, and 4% of the substrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary dragon fruit peel powder (DFPP)
Number of subjects: 0
Study: 27613551

Group type: EXPERIMENTAL
Intervention: Ultrasonically Activated Shears (UAS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional Monopolar Electrocautery (CME)
Number of subjects: 56
Study: 26002770

Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (100 mg)
Number of subjects: 16500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16500
Study: 25168405

Group type: EXPERIMENTAL
Intervention: Automatic tube potential selection (ATPS)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (constant current of 120 kV)
Number of subjects: 325
Study: 22325086

Group type: EXPERIMENTAL
Intervention: Valsartan add-on treatment
Number of subjects: 3031

Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 3031
Study: 19548410

Group type: EXPERIMENTAL
Intervention: 3.8-mm-diameter abutments (test group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5.5-mm-diameter abutments (control group)
Number of subjects: 22
Study: 17542340

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.15 microg/kg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.30 microg/kg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.60 microg/kg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (0.60 microg/kg)
Number of subjects: 0
Study: 14716711

Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy (4.2 mg/day)
Number of subjects: 96
Study: 11826488

Group type: EXPERIMENTAL
Intervention: Nitrullin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrullin in combination with VPN
Number of subjects: 0
Study: 9552059

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate and cranial radiotherapy (CRTX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate with folinic acid rescue and continuing intrathecal methotrexate (HDMTX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuing intrathecal methotrexate alone (ITMTX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatment groups (ITMTX, HDMTX, CRTX)
Number of subjects: 24
Study: 8141113

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis (intrathecal methotrexate plus cranial irradiation)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 62
Study: 3048935

Group type: EXPERIMENTAL
Intervention: Cefoxitin, 2 gm, given three times in a period of 10 hours.
Number of subjects: 352

Group type: COMPARATOR
Intervention: Ampicillin, 1 gm, four times daily, and metronidazole, 0.5 gm, three times daily, for 72 hours.
Number of subjects: 352
Study: 29030873

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 48
Study: 27002117

Group type: EXPERIMENTAL
Intervention: VTD (bortezomib-thalidomide-dexamethasone)
Number of subjects: 340

Group type: COMPARATOR
Intervention: VCD (bortezomib-cyclophosphamide-dexamethasone)
Number of subjects: 340
Study: 25686304

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs) intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE) intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both MAPs and SHE interventions
Number of subjects: 49
Study: 23211454

Group type: EXPERIMENTAL
Intervention: Lavender and Tea tree oils (group T) applied twice a day for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (group P) applied twice a day for 3 months
Number of subjects: 24
Study: 20809169

Group type: EXPERIMENTAL
Intervention: Resected popliteus tendon (Group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact popliteus tendon (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In vitro study with transected popliteus tendon
Number of subjects: 18

Group type: COMPARATOR
Intervention: In vitro study with intact popliteus tendon
Number of subjects: 18
Study: 17301736

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day for 3 days)
Number of subjects: 12
Study: 15390234

Group type: EXPERIMENTAL
Intervention: Intravenous injection of ascorbate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22076584

Group type: EXPERIMENTAL
Intervention: Nurse-prepared intra-arterial flush solutions with longer hang times
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-prepared intra-arterial flush solutions
Number of subjects: 0
Study: 9849048

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole (0.5 mg/kg body weight)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin 15000 IE, aspirin 500 mg i.v.)
Number of subjects: 763
Study: 7973073

Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specific knowledge of results (KR) conditions
Number of subjects: 0
Study: 2526009

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 400 mg teicoplanin 1, 3, 6 or 12 h prior to surgery
Number of subjects: 24
Study: 1097143

Group type: EXPERIMENTAL
Intervention: Amiloride (20 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Frusemide (80 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chlorothiazide (1000 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chlorothiazide, Frusemide, Ethacrynic acid
Number of subjects: 8
Study: 29331692

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 32
Study: 28407660

Group type: EXPERIMENTAL
Intervention: Calcium, 200 IU Vitamin D, and 90 µg Vitamin K supplementation
Number of subjects: 55
Study: 26081230

Group type: EXPERIMENTAL
Intervention: 3-piece aspheric IOL (Tecnis ZA9003, AMO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 1-piece aspheric IOL (Tecnis ZCB00, AMO)
Number of subjects: 49
Study: 23494570

Group type: EXPERIMENTAL
Intervention: Mexican PROGRESA/Oportunidades program (Conditional Cash Transfer program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21441068

Group type: EXPERIMENTAL
Intervention: Community based resistance training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Flexibility training
Number of subjects: 49
Study: 18502381

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 2
Study: 16596861

Group type: EXPERIMENTAL
Intervention: Nurse-led education and self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education and motivational interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audit and recall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary prevention
Number of subjects: 0
Study: 15248139

Group type: EXPERIMENTAL
Intervention: IL-2 (12-15 MIU/d) + ART
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 (6 MIU/d) + ART
Number of subjects: 30

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 11473880

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anesthesia (LEA) with lidocaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) with thiopental and isoflurane
Number of subjects: 19

Group type: COMPARATOR
Intervention: No anesthesia (Control)
Number of subjects: 19
Study: 9735687

Group type: EXPERIMENTAL
Intervention: Bilateral staple lung volume reduction surgery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unilateral staple lung volume reduction surgery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unilateral laser surgery
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery overall
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 300
Study: 8041983

Group type: EXPERIMENTAL
Intervention: Continuous perfusion of lidocaine 2% (group CP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Bolus administration of lidocaine 2% (group B)
Number of subjects: 31
Study: 2648150

Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg of phospholipid per kilogram of body weight [4 ml per kilogram])
Number of subjects: 159

Group type: COMPARATOR
Intervention: Air placebo (4 ml per kilogram)
Number of subjects: 159
Study: 4825114

Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis (5,000 IU mucous heparin sodium given two hours preoperatively and for five days post operatively)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unheparinized group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 300
Study: 31430484

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cocaine administration on day 10
Number of subjects: 40
Study: 28410818

Group type: EXPERIMENTAL
Intervention: Protocol group received initial and additional doses of rocuronium (0.6 mg.kg−1 and 10 mg, respectively); blockade reversal with neostigmine (50 μg.kg−1); time ≥ 15 minutes between reversion and extubation.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group received initial and additional doses of rocuronium, blockade reversal, neostigmine dose, and extubation time at the discretion of the anesthesiologist.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (patients with PORC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Protocol group (with PORC vs. without PORC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Entire study population (with PORC vs. without PORC)
Number of subjects: 122
Study: 24803523

Group type: EXPERIMENTAL
Intervention: Clinical dose of esmolol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Esmolol-treated groups (both clinical and subclinical doses)
Number of subjects: 3
Study: 23474997

Group type: EXPERIMENTAL
Intervention: Taekwondo training for 1 hour daily over three months
Number of subjects: 44

Group type: COMPARATOR
Intervention: DCD control group (no training)
Number of subjects: 44
Study: 21459745

Group type: EXPERIMENTAL
Intervention: High levels of family contact
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Moderate levels of family contact
Number of subjects: 180

Group type: COMPARATOR
Intervention: Low levels of family contact
Number of subjects: 180
Study: 19627690

Group type: EXPERIMENTAL
Intervention: ESCAPE‐knee pain
Number of subjects: 64

Group type: COMPARATOR
Intervention: Outpatient physiotherapy
Number of subjects: 64
Study: 16685298

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week before and one week after surgery (group I)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week after surgery (group II)
Number of subjects: 99
Study: 15374554

Group type: EXPERIMENTAL
Intervention: PAXpress
Number of subjects: 70

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 70
Study: 11389117

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 342

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 342
Study: 9431832

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone 1000 microg day-1 (F1000)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone 2000 microg day-1 (F2000)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 50 mg (PRED)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled placebo (PL)
Number of subjects: 10
Study: 8099863

Group type: EXPERIMENTAL
Intervention: 4 mg isamoltane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg isamoltane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3545744

Group type: EXPERIMENTAL
Intervention: 5 mg Nisoldipine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg Nisoldipine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg Nisoldipine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31987238

Group type: EXPERIMENTAL
Intervention: NutraforChol® (red yeast rice extract, guggulipid extract, chromium picolinate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NutraforChol®
Number of subjects: 0
Study: 31000333

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) added to a post-discharge disease management program (DMP)
Number of subjects: 278
Study: 30577818

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) by fathers for one hour every day until discharge
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional care (TC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 50
Study: 26886716

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 24444117

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate administered in the prehospital setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 21924644

Group type: EXPERIMENTAL
Intervention: Behavioral survey analysis
Number of subjects: 820
Study: 19708473

Group type: EXPERIMENTAL
Intervention: Sensory Integrative (SI) therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perceptual‐motor (PM) approach
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 18457248

Group type: EXPERIMENTAL
Intervention: Enteral immune nutrition (EIN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard enteral formula (EN)
Number of subjects: 20
Study: 15745668

Group type: EXPERIMENTAL
Intervention: Brief intervention (motivational intervention)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Minimal intervention (simple advice)
Number of subjects: 126
Study: 12229307

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg daily for three days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9637641

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isobaric or hyperbaric bupivacaine
Number of subjects: 80
Study: 7915989

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (LDMP)
Number of subjects: 31
Study: 2643500

Group type: EXPERIMENTAL
Intervention: Heparin sodium 10 units/mL
Number of subjects: 147

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection
Number of subjects: 147
Study: 4443869

Group type: EXPERIMENTAL
Intervention: Continuous phototherapy for 5 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (12 hr on and 12 hr off) for 5 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous phototherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 31277885

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (group 1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Warfarin (group 2)
Number of subjects: 84
Study: 27613888

Group type: EXPERIMENTAL
Intervention: COMB‐EXT with HV
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: COMB‐EXT without HV
Number of subjects: 34

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: COMB‐EXT (with or without HV)
Number of subjects: 34
Study: 26278685

Group type: EXPERIMENTAL
Intervention: Nanop Plus (10% HA, 0.2% NaF, nano‐HA/fluoride)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MI Paste Plus (casein phosphopeptide‐amorphous calcium phosphate, 0.2% NaF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: F (0.2% NaF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13